It is gradually becoming clear whether IonQ IONQ is a stronger investment bet than its quantum peers in 2025. With solid ...

Members of the STAR collaboration, a group of physicists collecting and analyzing data from particle collisions at the Relativistic Heavy Ion Collider (RHIC), have published a new high-precision ...

Completing Deep Dives into the Trilogy of Longstanding Gaps in Wildfire Prevention, Mitigation, and Response In the two ...

Remcom announces a suite of powerful new tools designed to address the evolving challenges of modern antenna design in the ...

RatedPower, a part of Enverus, has released 3D Energy, the company's new solar PV performance simulation tool. Designed for ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...

In this conversation, we explore how Advocate Health and Laerdal Medical are transforming patient safety through the power of simulation.

MoonLake Immunotherapeutics (MLTX) shares plunged after the company reported results from its Phase 3 trials for sonelokimab in hidradenitis suppurativa. The VELA-2 study missed its main goal, ...

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial ...

The MCU’s Phase 4 released instalments during 2021 and ’22, Phase 5 released during 2023, ’24, and ’25, and Phase 6 will run until 2027. Following this pattern, the MCU’s Phase 7 will likely span ...

CNN and random forest model to detect multiple faults in bifacial PV systems, including dust, shading, aging, and cracks. Using simulated I-V curves and a 180-day synthetic dataset, the model achieved ...